Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Viking Therapeutics (VKTX) over the last 12 years, with Q3 2025 value amounting to $100.4 million.

  • Viking Therapeutics' Cash & Equivalents rose 9936.84% to $100.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.4 million, marking a year-over-year increase of 9936.84%. This contributed to the annual value of $26.7 million for FY2024, which is 5194.9% down from last year.
  • Viking Therapeutics' Cash & Equivalents amounted to $100.4 million in Q3 2025, which was up 9936.84% from $33.9 million recorded in Q2 2025.
  • Viking Therapeutics' Cash & Equivalents' 5-year high stood at $195.6 million during Q1 2024, with a 5-year trough of $8.8 million in Q2 2021.
  • Over the past 5 years, Viking Therapeutics' median Cash & Equivalents value was $37.2 million (recorded in 2023), while the average stood at $59.5 million.
  • In the last 5 years, Viking Therapeutics' Cash & Equivalents surged by 162942.58% in 2022 and then plummeted by 8971.92% in 2023.
  • Over the past 5 years, Viking Therapeutics' Cash & Equivalents (Quarter) stood at $26.4 million in 2021, then soared by 38.91% to $36.6 million in 2022, then surged by 51.55% to $55.5 million in 2023, then plummeted by 51.95% to $26.7 million in 2024, then soared by 276.28% to $100.4 million in 2025.
  • Its Cash & Equivalents was $100.4 million in Q3 2025, compared to $33.9 million in Q2 2025 and $37.9 million in Q1 2025.